Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 33Neoplasms 18Colorectal Neoplasms 3Skin Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Skin Diseases 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Biliary Tract Neoplasms 1Advanced BRAF-mutant Cancers 1

Interventions

Ipilimumab 9pembrolizumab 6Nivolumab 4tremelimumab 3Paclitaxel 3Carboplatin 3spartalizumab 2lenvatinib 2durvalumab 2Doxorubicin 2Bevacizumab 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1osimertinib 1eribulin 1envafolimab 1cemiplimab 1balstilimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Pemetrexed 1Oxaliplatin 1Docetaxel 1Cisplatin 1Capecitabine 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Diabetes Mellitus, Insulin-Dependent, 12 × Vemurafenib × Clear all
NCT03013491 2025-06-17

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

CytomX Therapeutics

Phase 1/2 Terminated
196 enrolled 28 charts
Lymphoid

Diabetes Mellitus, Insulin-Dependent, 12, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡